Status: Not yet recruiting
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy. Participants will be randomized at a 1:2:2 ratio into three arms: Control Arm (continued medication), Direct Surgery Arm, and TDTP-RECIST Assessment Arm. The primary endpoint is Overall Survival (OS).
Participants needed: 270
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Oct 6, 2025Locations: 1
Eligibility criteria
Male or female aged 18-75 years; [+6]
Pathologically diagnosed hepatocellular carcinoma, combined hepatocellular-chola... [+7]